This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Acceleron Announces New Interim Phase 2 Sotatercept Clinical Data In Beta-Thalassemia To Be Presented At 2013 American Society Of Hematology Annual Meeting

Stocks in this article: XLRN

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that data in five abstracts for sotatercept and ACE-536, Acceleron’s programs to treat red blood cell disorders, will be presented at the 55 th American Society of Hematology (ASH) Annual Meeting and Exposition. The conference will take place on December 7-10 th at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

Key information to be presented include new interim data from the ongoing phase 2 clinical trial of sotatercept in patients with beta-thalassemia. Initial interim data from the 0.5 mg/kg dose level will be presented in a poster presentation by the first author Maria-Domenica Cappellini, M.D., University of Milan, Milan, Italy on Monday December 9 th from 6:00 – 8:00 PM CST in Hall E of the convention center. Acceleron has previously provided interim clinical data from the 0.1 mg/kg and 0.3 mg/kg dose levels in this trial.

Additionally, preclinical data from both the sotatercept and ACE-536 programs will be presented at the meeting. Both sotatercept and ACE-536 are being jointly developed through a global collaboration with Celgene Corporation. The presentations from Acceleron, Celgene and academic collaborators will take place as follows:

Sotatercept Clinical Data

Abstract title: “A Phase 2a, Open-Label, Dose-Finding Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults with Beta (β)-Thalassemia: Interim Results”Abstract number: 3448Session: 112. Thalassemia and Globin Gene Regulation: Poster IIIDate: Monday, December 9, 2013Time: 6:00 PM – 8:00 PM CST (Ernest N. Morial Convention Center, Hall E)

Sotatercept Preclinical Data

Abstract title: “Sotatercept Promotes Differentiation and Survival of Erythroid Progenitors by Blocking Inhibitory Effects of TGFβ Superfamily Members”Abstract number: 944Session: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism and Survival, Excluding Iron: Poster IDate: Saturday, December 7, 2013Time: 5:30 PM – 7:30 PM CST (Ernest N. Morial Convention Center, Hall E)

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs